<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="brief-report" xml:lang="en" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Schizophrenia (Heidelb)</journal-id><journal-id journal-id-type="iso-abbrev">Schizophrenia (Heidelb)</journal-id><journal-id journal-id-type="pmc-domain-id">4224</journal-id><journal-id journal-id-type="pmc-domain">schz</journal-id><journal-title-group><journal-title>Schizophrenia</journal-title></journal-title-group><issn pub-type="epub">2754-6993</issn><publisher><publisher-name>Nature Publishing Group</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC12475103</article-id><article-id pub-id-type="pmcid-ver">PMC12475103.1</article-id><article-id pub-id-type="pmcaid">12475103</article-id><article-id pub-id-type="pmcaiid">12475103</article-id><article-id pub-id-type="pmid">41006321</article-id><article-id pub-id-type="doi">10.1038/s41537-025-00665-3</article-id><article-id pub-id-type="publisher-id">665</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Comment</subject></subj-group></article-categories><title-group><article-title>Transient pre-baseline antipsychotic exposure (TPAE) is a prognostic specifier in clinical high risk for psychosis: evidence from the PSYSCAN consortium study</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0003-3709-4111</contrib-id><name name-style="western"><surname>Raballo</surname><given-names initials="A">Andrea</given-names></name><address><email>andrea.raballo@usi.ch</email></address><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Poletti</surname><given-names initials="M">Michele</given-names></name><xref ref-type="aff" rid="Aff3">3</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Preti</surname><given-names initials="A">Antonio</given-names></name><xref ref-type="aff" rid="Aff4">4</xref></contrib><aff id="Aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/03c4atk17</institution-id><institution-id institution-id-type="GRID">grid.29078.34</institution-id><institution-id institution-id-type="ISNI">0000 0001 2203 2861</institution-id><institution>Chair of Psychiatry, Faculty of Biomedical Sciences and REMEDI (Rethinking Mental Health through Clinical and Data Intelligence) Lab, Euler Institute, </institution><institution>University of Southern Switzerland, </institution></institution-wrap>Lugano, Switzerland </aff><aff id="Aff2"><label>2</label>Cantonal Sociopsychiatric Organisation, Mendrisio, Switzerland </aff><aff id="Aff3"><label>3</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/001bbwj30</institution-id><institution-id institution-id-type="GRID">grid.458453.b</institution-id><institution>Department of Mental Health and Pathological Addiction, Child and Adolescent Neuropsychiatry Service, </institution><institution>Azienda Unit&#224; Sanitaria Locale-IRCCS di Reggio Emilia, </institution></institution-wrap>Reggio Emilia, Italy </aff><aff id="Aff4"><label>4</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/048tbm396</institution-id><institution-id institution-id-type="GRID">grid.7605.4</institution-id><institution-id institution-id-type="ISNI">0000 0001 2336 6580</institution-id><institution>Department of Neuroscience, </institution><institution>University of Turin, </institution></institution-wrap>Turin, Italy </aff></contrib-group><pub-date pub-type="epub"><day>26</day><month>9</month><year>2025</year></pub-date><pub-date pub-type="collection"><year>2025</year></pub-date><volume>11</volume><issue>1</issue><issue-id pub-id-type="pmc-issue-id">478459</issue-id><elocation-id>119</elocation-id><history><date date-type="received"><day>27</day><month>5</month><year>2025</year></date><date date-type="accepted"><day>1</day><month>8</month><year>2025</year></date></history><pub-history><event event-type="pmc-release"><date><day>26</day><month>09</month><year>2025</year></date></event><event event-type="pmc-live"><date><day>28</day><month>09</month><year>2025</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2025-09-28 00:25:15.170"><day>28</day><month>09</month><year>2025</year></date></event></pub-history><permissions><copyright-statement>&#169; The Author(s) 2025</copyright-statement><copyright-year>2025</copyright-year><license><ali:license_ref specific-use="textmining" content-type="ccbyncndlicense">https://creativecommons.org/licenses/by-nc-nd/4.0/</ali:license_ref><license-p><bold>Open Access</bold> This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article&#8217;s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article&#8217;s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">http://creativecommons.org/licenses/by-nc-nd/4.0/</ext-link>.</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="41537_2025_Article_665.pdf"/><abstract id="Abs1" abstract-type="teaser"><p id="Par1">Baseline exposure to antipsychotics (AP) in individuals at clinical high risk for psychosis (CHR-P) has emerged as a robust prognostic marker for transition to psychosis. Recent meta-analyses show that CHR-P individuals receiving APs at study entry exhibit significantly higher transition rates, with a temporally discernible dose-effect pattern. To test the replicability of this prognostic signal, we conducted a secondary analysis of publicly available supplementary data from the PSYSCAN Consortium. Despite applying strict inclusion criteria that limited AP exposure to &#8804;30 days of low-dose treatment, transition rates in PSYSCAN remained higher in the AP-exposed group (28.0% vs. 12.2%; RR 2.29). Notably, this finding was not emphasized in the primary publication, thus representing inadvertent yet compelling support for the prognostic relevance of early AP need. These results reinforce the rationale for future CHR-P studies to adopt AP-na&#239;ve condition as a stratification criterion to avoid pharmacologically induced diagnostic obscuration and improve the precision of risk modelling. Furthermore, they corroborate the PSYSCAN-derived operational notion of <italic toggle="yes">transient pre-baseline AP exposure</italic> (TPAE) (i.e., &#8804;30 cumulative days in the 3 months preceding baseline, at subtherapeutic doses) as a pragmatic and testable prognostic specifier that supplements existing CHR-P criteria.</p></abstract><kwd-group kwd-group-type="npg-subject"><title>Subject terms</title><kwd>Biomarkers</kwd><kwd>Psychosis</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#169; Springer Nature Limited 2025</meta-value></custom-meta></custom-meta-group></article-meta></front><body><p id="Par2">Recent meta-analyses suggest that ongoing pharmacotherapy at inception, particularly antipsychotic exposure, represents a key prognostic modulator for psychosis transition in help-seeking individuals at clinical high risk for psychosis (CHR-P)<sup><xref ref-type="bibr" rid="CR1">1</xref>&#8211;<xref ref-type="bibr" rid="CR5">5</xref></sup>.</p><p id="Par3">In particular, with respect to AP, those cumulative evidences indicate that:<list list-type="order"><list-item><p id="Par4">baseline pharmacological exposure to antipsychotics (AP) in individuals of CHR-P cohorts is associated with an increased risk of transitioning to psychosis in comparison with non-exposed individuals (32.9% vs. 20.6 Risk Ratio 1.56)<sup><xref ref-type="bibr" rid="CR3">3</xref></sup>;</p></list-item><list-item><p id="Par5">such negative prognostic effect is not due to differential enrichment strategies (i.e., pre-test risk enrichment);<sup><xref ref-type="bibr" rid="CR6">6</xref></sup></p></list-item><list-item><p id="Par6">the temporal dynamics of transition to psychosis differs in AP-exposed vs. AP-naive CHR, i.e., baseline AP exposure in CHR-P is associated with a persistently higher risk of transition at follow up<sup><xref ref-type="bibr" rid="CR4">4</xref></sup>;</p></list-item><list-item><p id="Par7">such effect follows a dose-response pattern: among CHR-P individuals exposed to antipsychotics (APs) at baseline, those who later transitioned to psychosis had received a baseline AP prescription within the range of the mean effective chlorpromazine equivalent daily dose<sup><xref ref-type="bibr" rid="CR5">5</xref></sup>.</p></list-item></list></p><p id="Par8">Following meta-analytical evidences, the prognostic risk associated with baseline AP exposure was independently confirmed in CHR-P cohorts<sup><xref ref-type="bibr" rid="CR7">7</xref>&#8211;<xref ref-type="bibr" rid="CR10">10</xref></sup> and is clinically interpreted not as a paradoxical iatrogenic effect but rather as a clinical proxy of increased baseline clinical severity which escapes the standard CHR-P criteria<sup><xref ref-type="bibr" rid="CR11">11</xref>,<xref ref-type="bibr" rid="CR12">12</xref></sup>. This suggests that AP-treated individuals, despite being classified as CHR-P, may functionally represent pharmacologically attenuated first-episode psychosis, reducing the diagnostic resolution of current CHR-P stratification frameworks<sup><xref ref-type="bibr" rid="CR13">13</xref></sup> (which are largely agnostic to baseline pharmacological exposures)<sup><xref ref-type="bibr" rid="CR14">14</xref></sup>.</p><p id="Par9">Furthermore, it must be emphasized that all available treatment guidelines for individuals at CHR-P almost unanimously do not indicate AP as first therapeutic option to prevent transition to psychosis (see ref. <sup><xref ref-type="bibr" rid="CR15">15</xref></sup> for an updated synopsis), suggesting that exposure to AP in help-seekers undergoing CHR-P assessment is a relevant clinical-anamnestic detail. In light of such increasing empirical evidence<sup><xref ref-type="bibr" rid="CR1">1</xref>,<xref ref-type="bibr" rid="CR4">4</xref>&#8211;<xref ref-type="bibr" rid="CR10">10</xref></sup>, the recently launched &#8220;Largest Global Prospective Cohort Study of Clinical High Risk for Psychosis&#8221; under the Accelerating Medicines Partnership&#174; Schizophrenia (AMP&#174; SCZ)<sup><xref ref-type="bibr" rid="CR16">16</xref></sup> has taken an important step by listing &#8220;current antipsychotic medication at the time of baseline assessment&#8221; as an exclusion criterion, ensuring more accurate assessments of the natural course of psychosis risk.</p><p id="Par10">In contrast, the PSYSCAN project<sup><xref ref-type="bibr" rid="CR17">17</xref></sup> offers a unique multinational platform to critically evaluate the prognostic role of AP treatment in CHR-P individuals. Indeed, PSYSCAN&#8217;s inclusion of participants with limited, carefully documented AP exposure (&#8201;&#8804;&#8201;30 days at subtherapeutic doses) creates an ideal natural platform to directly test the negative prognostic association found in meta-analyses of CHR-P help-seekers. We therefore conducted a secondary conceptually-driven analysis of PSYSCAN data to determine whether even a circumscribed, low dose and time-limited AP exposure before inception (as per PSYSCAN specific exclusion criteria) impacts the imminent risk of transition to psychosis.</p><sec id="Sec1"><title>PSYSCAN consortium: operational exclusion criteria and the naturalistic subgroup CHR-P individuals with brief, low-dose AP exposure</title><p id="Par11">According to Tognin et al.<sup><xref ref-type="bibr" rid="CR17">17</xref></sup>, in a presumably cautious, albeit undeclared, attempt to mitigate the potential confounding influence of baseline antipsychotic (AP) exposure, the PSYSCAN study adopted relatively strict inclusion criteria, i.e., <italic toggle="yes">excluding individuals who had received AP treatment for more than 30 cumulative days within the 3 months prior to baseline, and only at doses deemed adequate for first-episode psychosis treatment</italic>.</p><p id="Par12">Nevertheless, this protocol allowed for the inclusion of CHR-P individuals with brief, low-dose AP exposure [(Transient pre-baseline antipsychotic exposure (TPAE); See Box <xref rid="Sec2" ref-type="sec">1</xref>], thereby inadvertently creating a naturalistic subgroup for exploratory prognostic analysis.</p><sec id="Sec2"><boxed-text position="float" orientation="portrait"><label>Box 1 Transient Pre-Baseline Antipsychotic Exposure (TPAE): a PSYSCAN-derived operational prognostic specifier</label><p id="Par13">Definition <italic toggle="yes">Transient Pre-Baseline Antipsychotic Exposure (TPAE)</italic> refers to a distinct subgroup of CHR-P individuals who meet the following criteria:<list list-type="bullet"><list-item><p id="Par14"><bold>Antipsychotic treatment duration</bold>: &#8804;30 cumulative days</p></list-item><list-item><p id="Par15"><bold>Timing</bold>: Within the 3 months prior to baseline assessment</p></list-item><list-item><p id="Par16"><bold>Dosage</bold>: Subtherapeutic (below standard First-Episode Psychosis treatment thresholds)</p></list-item><list-item><p id="Par17"><bold>Clinical status during exposure</bold>: No evidence of full-threshold psychosis</p></list-item><list-item><p id="Par18"><bold>CHR-P status at baseline</bold>: Maintained (per CAARMS, SIPS, SPI-A, or equivalent)</p></list-item></list></p><p id="Par19">This construct is derived from PSYSCAN study parameters and captures short-term, pre-enrollment AP exposure that has concluded or is clinically negligible by the time of formal CHR-P assessment.</p><p id="Par20">
<bold>Prognostic Relevance</bold>
</p><p id="Par21">TPAE functions as a <bold>prognostic specifier</bold> within the CHR-P framework. In the PSYSCAN cohort, individuals with TPAE status exhibited a <bold>transition rate of 28.0%</bold>, significantly higher than their AP-na&#239;ve counterparts (12.2%), despite the controlled, low-dose exposure window.</p><p id="Par22">
<bold>Comparison with General Baseline AP Exposure</bold>
<table-wrap id="Taba" position="float" orientation="portrait"><table frame="hsides" rules="groups"><thead><tr><th colspan="1" rowspan="1">Feature</th><th colspan="1" rowspan="1">TPAE</th><th colspan="1" rowspan="1">General Baseline AP Exposure</th></tr></thead><tbody><tr><td colspan="1" rowspan="1">
<bold>Exposure duration</bold>
</td><td colspan="1" rowspan="1">&#8804;30 days</td><td colspan="1" rowspan="1">Unrestricted</td></tr><tr><td colspan="1" rowspan="1">
<bold>Exposure window</bold>
</td><td colspan="1" rowspan="1">3 months pre-baseline</td><td colspan="1" rowspan="1">Often undefined</td></tr><tr><td colspan="1" rowspan="1">
<bold>Dose level</bold>
</td><td colspan="1" rowspan="1">Subtherapeutic</td><td colspan="1" rowspan="1">Any dose, including therapeutic</td></tr><tr><td colspan="1" rowspan="1">
<bold>AP status at baseline</bold>
</td><td colspan="1" rowspan="1">Discontinued or minimal</td><td colspan="1" rowspan="1">May be ongoing</td></tr><tr><td colspan="1" rowspan="1">
<bold>Definition source</bold>
</td><td colspan="1" rowspan="1">Derived from PSYSCAN exclusion criteria</td><td colspan="1" rowspan="1">Heterogeneous across studies</td></tr><tr><td colspan="1" rowspan="1">
<bold>Prognostic signal (RR)</bold>
</td><td colspan="1" rowspan="1">2.29</td><td colspan="1" rowspan="1">~1.56 (meta-analytic estimate)</td></tr><tr><td colspan="1" rowspan="1">
<bold>Clinical utility</bold>
</td><td colspan="1" rowspan="1">Reproducible and operationally defined; stratifies high-risk CHR-P cases.</td><td colspan="1" rowspan="1">Clinically indicative, yet with low granularity (despite meta-analytic evidence of dose-effect pattern)</td></tr><tr><td colspan="1" rowspan="1">
<bold>Interpretation</bold>
</td><td colspan="1" rowspan="1">TPAE status increases the prognostic precision of CHR-P classification, indexing a CHR-P subgroup at increased risk of transition to psychosis.</td><td colspan="1" rowspan="1">Baseline antipsychotic (AP) exposure is a broad proxy for elevated imminent risk of psychosis transition in CHR-P individuals, further substantiated by meta-analytical evidence demonstrating a dose-effect relationship</td></tr></tbody></table></table-wrap>
</p></boxed-text></sec><sec id="Sec3"><title>PSYSCAN consortium: supplementary data on AP exposure</title><p id="Par23">Although not examined or discussed in the main text of the PSYSCAN article, the Supplementary Material (Table S4) discloses a striking discrepancy in transition rates between CHR-P individuals exposed to antipsychotics (AP) at baseline and those who were AP-na&#239;ve: 28.0% (7 of 25) versus 12.2% (26 of 213), corresponding to a relative risk of 2.29 (95% CI: 1.11&#8211;4.73)<sup><xref ref-type="bibr" rid="CR18">18</xref></sup>. This difference emerged despite the study&#8217;s deliberate exclusion of individuals with prolonged or high-dose AP exposure (specifically, those treated for more than 30 cumulative days in the 3 months prior to baseline at dosages considered therapeutically adequate for a first-episode psychosis). The fact that such a prognostic signal surfaced even under these restrictive conditions underscores the significance of minimal baseline AP exposure as an indicator of heightened transition risk.</p><p id="Par24">Notably, because this differential transition rate was reported only in supplementary materials and not interpreted or emphasized by the authors, it gains a distinct layer of credibility: the finding is free from confirmatory bias and thus represents a form of inadvertent evidence. This strengthens the broader empirical signal previously identified in meta-analyses, which consistently link baseline AP exposure in CHR-P individuals to a persistently elevated risk of psychosis onset, likely reflecting unmeasured clinical severity that escapes current CHR-P stratification models. Moreover, in PSYSCAN study it was not possible to directly compare symptomatic clinical severity between TPAE and AP-na&#239;ve subgroups, leaving open the possibility that unmeasured baseline psychopathology may confound the observed effect. Additionally, given the multi-centre nature of PSYSCAN, site-level variability in prescribing thresholds may have introduced selection bias, possibly weakening the generalizability of the results, deserving further empirical confirmation. Finally, the analysis did not control for covariates; however, the RR consistency with prior meta-analyses<sup><xref ref-type="bibr" rid="CR1">1</xref>,<xref ref-type="bibr" rid="CR4">4</xref>,<xref ref-type="bibr" rid="CR5">5</xref></sup> supports TPAE&#8217;s utility.</p><p id="Par25">Accordingly, this derivative insight from the PSYSCAN data supports the call for a new generation of CHR-P studies based on explicitly AP-na&#239;ve cohorts. Such a methodological refinement is critical to disentangle intrinsic transition risk from pharmacologically modulated clinical presentations and to avoid conflating attenuated psychosis syndromes with partially treated early psychosis (or other previous clinical conditions not transparently detailed). Within the framework of precision psychiatry, this distinction is intuitively essential for improving diagnostic clarity, enhancing prognostic accuracy, and refining individualized prevention strategies.</p></sec></sec><sec id="Sec4" sec-type="conclusion"><title>Conclusions</title><p id="Par26">This finding suggests that it is not merely the characteristics of antipsychotic (AP) treatment, such as dose or duration, that are prognostically relevant, but rather the very need for AP intervention that serves as a significant clinical indicator of heightened risk for transition to psychosis in help-seekers referred for CHR-P assessment. Such need likely reflects an underlying severity that may not be fully captured by psychometric tools alone and is certainly invisible through current CHR-P stratification<sup><xref ref-type="bibr" rid="CR1">1</xref>,<xref ref-type="bibr" rid="CR4">4</xref>&#8211;<xref ref-type="bibr" rid="CR6">6</xref>,<xref ref-type="bibr" rid="CR11">11</xref></sup>.</p><p id="Par27">What makes this specific evidence about TPAE prognostic value particularly compelling is its source: it does not arise from CHR-P cohorts where AP use was unrestricted at baseline<sup><xref ref-type="bibr" rid="CR19">19</xref></sup>, but rather from the PSYSCAN cohort, which applied explicit exclusion criteria to limit prior AP exposure to short-term, low-dose use. This design unintentionally created a naturalistic gradient of AP exposure, allowing an indirect yet powerful test of its prognostic meaning.</p><p id="Par28">Building on this, and in the spirit of enhancing precision psychiatry, our analysis underscores the necessity for a next generation of CHR-P studies. These should incorporate transparent, systematic documentation of pharmacological exposures and their related clinical needs, before inception, at baseline and after inception (from baseline to follow ups), and prioritize the recruitment of AP-na&#239;ve individuals to unmask true risk trajectories<sup><xref ref-type="bibr" rid="CR20">20</xref></sup>. As converging evidence suggests, baseline AP use is a non-neutral variable: it may confound diagnostic classification and obscure the distinction between an attenuated psychosis syndrome and a pharmacologically attenuated first-episode psychosis<sup><xref ref-type="bibr" rid="CR11">11</xref></sup>.</p><p id="Par29">Within a refined clinical and research framework, AP exposure should not be dismissed as a contingent, background variable, but rather recognized as both a prognostic stratifier (at inception) and a functional proxy for early conversion (at follow up). Consequently, stratifying CHR-P individuals based on AP-na&#239;ve condition versus AP-treatment should be adopted as a gold standard in both research and clinical monitoring and TPAE status should be systematically recorded and reported to refine prognostic models. This approach is critical to improving risk prediction, refining case conceptualization, and ultimately achieving the promise of individualized preventive psychiatry.</p></sec></body><back><fn-group><fn><p><bold>Publisher&#8217;s note</bold> Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p></fn></fn-group><notes notes-type="author-contribution"><title>Author contributions</title><p>A.R., M.P. and A.P. equally conceived the paper and wrote the manuscript. All authors agreed on the final version.</p></notes><notes notes-type="data-availability"><title>Data availability</title><p>The data supporting the findings of this study are publicly accessible via the supplementary materials of the following publication: Tognin S, Vieira S, Oliver D, Cullen AE, Kempton MJ, Fusar-Poli P, Mechelli A, Dazzan P, Merritt K, Maat A, de Haan L, Lawrie SM, van Amelsvoort T, Arango C, Nelson B, Galderisi S, Bressan R, Kwon JS, Mizrahi R; PSYSCAN Consortium; Kahn RS, McGuire P. PSYSCAN multi-centre study: baseline characteristics and clinical outcomes of the clinical high risk for psychosis sample. Schizophrenia (Heidelb). 2025 Apr 17;11(1):66. 10.1038/s41537-025-00598-x. PMID: 40246889; PMCID: PMC12006469. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://static-content.springer.com/esm/art%3A10.1038%2Fs41537-025-00598-x/MediaObjects/41537_2025_598_MOESM1_ESM.docx">https://static-content.springer.com/esm/art%3A10.1038%2Fs41537-025-00598-x/MediaObjects/41537_2025_598_MOESM1_ESM.docx</ext-link>.</p></notes><notes id="FPar1" notes-type="COI-statement"><title>Competing interests</title><p id="Par30">The authors declare no competing interests.</p></notes><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><citation-alternatives><element-citation id="ec-CR1" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Raballo</surname><given-names>A</given-names></name><etal/></person-group><article-title>Meta-analyzing the prevalence and prognostic effect of antipsychotic exposure in clinical high-risk (CHR): when things are not what they seem</article-title><source>Psychol. Med</source><year>2020</year><volume>50</volume><fpage>2673</fpage><lpage>2681</lpage><pub-id pub-id-type="doi">10.1017/S0033291720004237</pub-id><pub-id pub-id-type="pmid">33198845</pub-id></element-citation><mixed-citation id="mc-CR1" publication-type="journal">Raballo, A. et al. Meta-analyzing the prevalence and prognostic effect of antipsychotic exposure in clinical high-risk (CHR): when things are not what they seem. <italic toggle="yes">Psychol. Med</italic>. <bold>50</bold>, 2673&#8211;2681 (2020).<pub-id pub-id-type="pmid">33198845</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1017/S0033291720004237</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR2"><label>2.</label><citation-alternatives><element-citation id="ec-CR2" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Raballo</surname><given-names>A</given-names></name><etal/></person-group><article-title>Do antidepressants prevent transition to psychosis in individuals at clinical high-risk (CHR-P)? Systematic review and meta-analysis</article-title><source>Psychol. Med</source><year>2023</year><volume>53</volume><fpage>4550</fpage><lpage>4560</lpage><pub-id pub-id-type="doi">10.1017/S0033291722001428</pub-id><pub-id pub-id-type="pmid">35655405</pub-id></element-citation><mixed-citation id="mc-CR2" publication-type="journal">Raballo, A. et al. Do antidepressants prevent transition to psychosis in individuals at clinical high-risk (CHR-P)? Systematic review and meta-analysis. <italic toggle="yes">Psychol. Med</italic>. <bold>53</bold>, 4550&#8211;4560 (2023).<pub-id pub-id-type="pmid">35655405</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1017/S0033291722001428</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR3"><label>3.</label><citation-alternatives><element-citation id="ec-CR3" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Raballo</surname><given-names>A</given-names></name><etal/></person-group><article-title>Baseline benzodiazepine exposure is associated with greater risk of transition in clinical high-risk for psychosis (CHR-P): a meta-analysis</article-title><source>Psychol. Med</source><year>2023</year><volume>53</volume><fpage>6417</fpage><lpage>6423</lpage><pub-id pub-id-type="doi">10.1017/S0033291723002180</pub-id><pub-id pub-id-type="pmid">37609894</pub-id></element-citation><mixed-citation id="mc-CR3" publication-type="journal">Raballo, A. et al. Baseline benzodiazepine exposure is associated with greater risk of transition in clinical high-risk for psychosis (CHR-P): a meta-analysis. <italic toggle="yes">Psychol. Med</italic>. <bold>53</bold>, 6417&#8211;6423 (2023).<pub-id pub-id-type="pmid">37609894</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1017/S0033291723002180</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR4"><label>4.</label><citation-alternatives><element-citation id="ec-CR4" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Raballo</surname><given-names>A</given-names></name><etal/></person-group><article-title>The temporal dynamics of transition to psychosis in individuals at clinical high-risk (CHR-P) shows negative prognostic effects of baseline antipsychotic exposure: a meta-analysis</article-title><source>Transl. Psychiatry</source><year>2023</year><volume>13</volume><fpage>112</fpage><pub-id pub-id-type="doi">10.1038/s41398-023-02405-6</pub-id><pub-id pub-id-type="pmid">37019886</pub-id><pub-id pub-id-type="pmcid">PMC10076303</pub-id></element-citation><mixed-citation id="mc-CR4" publication-type="journal">Raballo, A. et al. The temporal dynamics of transition to psychosis in individuals at clinical high-risk (CHR-P) shows negative prognostic effects of baseline antipsychotic exposure: a meta-analysis. <italic toggle="yes">Transl. Psychiatry</italic><bold>13</bold>, 112 (2023).<pub-id pub-id-type="pmid">37019886</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41398-023-02405-6</pub-id><pub-id pub-id-type="pmcid">PMC10076303</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR5"><label>5.</label><citation-alternatives><element-citation id="ec-CR5" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Raballo</surname><given-names>A</given-names></name><etal/></person-group><article-title>Baseline Antipsychotic Dose and Transition to Psychosis in Individuals at Clinical High Risk: A Systematic Review and Meta-Analysis</article-title><source>JAMA Psychiatry</source><year>2024</year><volume>81</volume><fpage>727</fpage><lpage>730</lpage><pub-id pub-id-type="doi">10.1001/jamapsychiatry.2024.0178</pub-id><pub-id pub-id-type="pmid">38506802</pub-id><pub-id pub-id-type="pmcid">PMC10955337</pub-id></element-citation><mixed-citation id="mc-CR5" publication-type="journal">Raballo, A. et al. Baseline Antipsychotic Dose and Transition to Psychosis in Individuals at Clinical High Risk: A Systematic Review and Meta-Analysis. <italic toggle="yes">JAMA Psychiatry</italic><bold>81</bold>, 727&#8211;730 (2024).<pub-id pub-id-type="pmid">38506802</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1001/jamapsychiatry.2024.0178</pub-id><pub-id pub-id-type="pmcid">PMC10955337</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR6"><label>6.</label><citation-alternatives><element-citation id="ec-CR6" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Raballo</surname><given-names>A</given-names></name><etal/></person-group><article-title>Negative Prognostic Effect of Baseline Antipsychotic Exposure in Clinical High Risk for Psychosis (CHR-P): Is Pre-Test Risk Enrichment the Hidden Culprit?</article-title><source>Int J. Neuropsychopharmacol.</source><year>2021</year><volume>24</volume><fpage>710</fpage><lpage>720</lpage><pub-id pub-id-type="doi">10.1093/ijnp/pyab030</pub-id><pub-id pub-id-type="pmid">34036323</pub-id><pub-id pub-id-type="pmcid">PMC8453273</pub-id></element-citation><mixed-citation id="mc-CR6" publication-type="journal">Raballo, A. et al. Negative Prognostic Effect of Baseline Antipsychotic Exposure in Clinical High Risk for Psychosis (CHR-P): Is Pre-Test Risk Enrichment the Hidden Culprit?. <italic toggle="yes">Int J. Neuropsychopharmacol.</italic><bold>24</bold>, 710&#8211;720 (2021).<pub-id pub-id-type="pmid">34036323</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/ijnp/pyab030</pub-id><pub-id pub-id-type="pmcid">PMC8453273</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR7"><label>7.</label><citation-alternatives><element-citation id="ec-CR7" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Preti</surname><given-names>A</given-names></name><etal/></person-group><article-title>Antipsychotics are related to psychometric conversion to psychosis in ultra-high-risk youth</article-title><source>Early Inter. Psychiatry</source><year>2022</year><volume>16</volume><fpage>342</fpage><lpage>351</lpage><pub-id pub-id-type="doi">10.1111/eip.13158</pub-id><pub-id pub-id-type="pmcid">PMC9291179</pub-id><pub-id pub-id-type="pmid">33951751</pub-id></element-citation><mixed-citation id="mc-CR7" publication-type="journal">Preti, A. et al. Antipsychotics are related to psychometric conversion to psychosis in ultra-high-risk youth. <italic toggle="yes">Early Inter. Psychiatry</italic><bold>16</bold>, 342&#8211;351 (2022).<pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/eip.13158</pub-id><pub-id pub-id-type="pmcid">PMC9291179</pub-id><pub-id pub-id-type="pmid">33951751</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR8"><label>8.</label><citation-alternatives><element-citation id="ec-CR8" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pelizza</surname><given-names>L</given-names></name><etal/></person-group><article-title>Baseline antipsychotic prescription and short-term outcome indicators in individuals at clinical high-risk for psychosis: Findings from the Parma At-Risk Mental States (PARMS) program</article-title><source>Early Inter. Psychiatry</source><year>2024</year><volume>18</volume><fpage>71</fpage><lpage>81</lpage><pub-id pub-id-type="doi">10.1111/eip.13434</pub-id><pub-id pub-id-type="pmid">37194411</pub-id></element-citation><mixed-citation id="mc-CR8" publication-type="journal">Pelizza, L. et al. Baseline antipsychotic prescription and short-term outcome indicators in individuals at clinical high-risk for psychosis: Findings from the Parma At-Risk Mental States (PARMS) program. <italic toggle="yes">Early Inter. Psychiatry</italic><bold>18</bold>, 71&#8211;81 (2024).<pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/eip.13434</pub-id><pub-id pub-id-type="pmid">37194411</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR9"><label>9.</label><citation-alternatives><element-citation id="ec-CR9" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zeng</surname><given-names>J</given-names></name><etal/></person-group><article-title>Antipsychotic Exposure in Clinical High Risk of Psychosis: Empirical Insights From a Large Cohort Study</article-title><source>J. Clin. Psychiatry</source><year>2022</year><volume>83</volume><fpage>21m14092</fpage><pub-id pub-id-type="doi">10.4088/JCP.21m14092</pub-id><pub-id pub-id-type="pmid">35324095</pub-id></element-citation><mixed-citation id="mc-CR9" publication-type="journal">Zeng, J. et al. Antipsychotic Exposure in Clinical High Risk of Psychosis: Empirical Insights From a Large Cohort Study. <italic toggle="yes">J. Clin. Psychiatry</italic><bold>83</bold>, 21m14092 (2022).<pub-id pub-id-type="pmid">35324095</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.4088/JCP.21m14092</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR10"><label>10.</label><citation-alternatives><element-citation id="ec-CR10" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>T</given-names></name><etal/></person-group><article-title>Antipsychotic prescription, assumption and conversion to psychosis: resolving missing clinical links to optimize prevention through precision</article-title><source>Schizophrenia Heidelb.</source><year>2022</year><volume>8</volume><fpage>4</fpage><pub-id pub-id-type="pmid">35853891</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41537-022-00254-8</pub-id><pub-id pub-id-type="pmcid">PMC9261109</pub-id></element-citation><mixed-citation id="mc-CR10" publication-type="journal">Zhang, T. et al. Antipsychotic prescription, assumption and conversion to psychosis: resolving missing clinical links to optimize prevention through precision. <italic toggle="yes">Schizophrenia Heidelb.</italic><bold>8</bold>, 4 (2022).<pub-id pub-id-type="pmid">35853891</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41537-022-00254-8</pub-id><pub-id pub-id-type="pmcid">PMC9261109</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR11"><label>11.</label><citation-alternatives><element-citation id="ec-CR11" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Raballo</surname><given-names>A</given-names></name><etal/></person-group><article-title>Attenuated Psychosis Syndrome or Pharmacologically Attenuated First-Episode Psychosis?: An Undesirably Widespread Confounder</article-title><source>JAMA Psychiatry</source><year>2020</year><volume>77</volume><fpage>1213</fpage><lpage>1214</lpage><pub-id pub-id-type="doi">10.1001/jamapsychiatry.2020.1634</pub-id><pub-id pub-id-type="pmid">32639551</pub-id></element-citation><mixed-citation id="mc-CR11" publication-type="journal">Raballo, A. et al. Attenuated Psychosis Syndrome or Pharmacologically Attenuated First-Episode Psychosis?: An Undesirably Widespread Confounder. <italic toggle="yes">JAMA Psychiatry</italic><bold>77</bold>, 1213&#8211;1214 (2020).<pub-id pub-id-type="pmid">32639551</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1001/jamapsychiatry.2020.1634</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR12"><label>12.</label><citation-alternatives><element-citation id="ec-CR12" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Raballo</surname><given-names>A</given-names></name><etal/></person-group><article-title>Antipsychotic treatment in clinical high risk for psychosis: Protective, iatrogenic or further risk flag?</article-title><source>Aust. N. Z. J. Psychiatry</source><year>2021</year><volume>55</volume><fpage>442</fpage><lpage>444</lpage><pub-id pub-id-type="doi">10.1177/0004867420984836</pub-id><pub-id pub-id-type="pmid">33426910</pub-id></element-citation><mixed-citation id="mc-CR12" publication-type="journal">Raballo, A. et al. Antipsychotic treatment in clinical high risk for psychosis: Protective, iatrogenic or further risk flag?. <italic toggle="yes">Aust. N. Z. J. Psychiatry</italic><bold>55</bold>, 442&#8211;444 (2021).<pub-id pub-id-type="pmid">33426910</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1177/0004867420984836</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR13"><label>13.</label><citation-alternatives><element-citation id="ec-CR13" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sanfelici</surname><given-names>R</given-names></name><etal/></person-group><article-title>Individualized Diagnostic and Prognostic Models for Patients With Psychosis Risk Syndromes: A Meta-analytic View on the State of the Art</article-title><source>Biol. Psychiatry</source><year>2020</year><volume>15</volume><fpage>349</fpage><lpage>360</lpage><pub-id pub-id-type="doi">10.1016/j.biopsych.2020.02.009</pub-id><pub-id pub-id-type="pmid">32305218</pub-id></element-citation><mixed-citation id="mc-CR13" publication-type="journal">Sanfelici, R. et al. Individualized Diagnostic and Prognostic Models for Patients With Psychosis Risk Syndromes: A Meta-analytic View on the State of the Art. <italic toggle="yes">Biol. Psychiatry</italic><bold>15</bold>, 349&#8211;360 (2020).<pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.biopsych.2020.02.009</pub-id><pub-id pub-id-type="pmid">32305218</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR14"><label>14.</label><citation-alternatives><element-citation id="ec-CR14" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Raballo</surname><given-names>A</given-names></name><etal/></person-group><article-title>Individualized Diagnostic and Prognostic Models for Psychosis Risk Syndromes: Do Not Underestimate Antipsychotic Exposure</article-title><source>Biol. Psychiatry</source><year>2021</year><volume>90</volume><fpage>e33</fpage><lpage>e35</lpage><pub-id pub-id-type="doi">10.1016/j.biopsych.2021.01.020</pub-id><pub-id pub-id-type="pmid">34001370</pub-id></element-citation><mixed-citation id="mc-CR14" publication-type="journal">Raballo, A. et al. Individualized Diagnostic and Prognostic Models for Psychosis Risk Syndromes: Do Not Underestimate Antipsychotic Exposure. <italic toggle="yes">Biol. Psychiatry</italic><bold>90</bold>, e33&#8211;e35 (2021).<pub-id pub-id-type="pmid">34001370</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.biopsych.2021.01.020</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR15"><label>15.</label><citation-alternatives><element-citation id="ec-CR15" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Poletti</surname><given-names>M</given-names></name><etal/></person-group><article-title>Clinical High-Risk for Psychosis (CHR-P) circa 2024: Synoptic analysis and synthesis of contemporary treatment guidelines</article-title><source>Asian J. Psychiatr.</source><year>2024</year><volume>100</volume><fpage>104142</fpage><pub-id pub-id-type="doi">10.1016/j.ajp.2024.104142</pub-id><pub-id pub-id-type="pmid">39083954</pub-id></element-citation><mixed-citation id="mc-CR15" publication-type="journal">Poletti, M. et al. Clinical High-Risk for Psychosis (CHR-P) circa 2024: Synoptic analysis and synthesis of contemporary treatment guidelines. <italic toggle="yes">Asian J. Psychiatr.</italic><bold>100</bold>, 104142 (2024).<pub-id pub-id-type="pmid">39083954</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.ajp.2024.104142</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR16"><label>16.</label><citation-alternatives><element-citation id="ec-CR16" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wannan</surname><given-names>CMJ</given-names></name><etal/></person-group><article-title>Accelerating Medicines Partnership&#174; Schizophrenia (AMP&#174; SCZ): Rationale and Study Design of the Largest Global Prospective Cohort Study of Clinical High Risk for Psychosis</article-title><source>Schizophr. Bull.</source><year>2024</year><volume>50</volume><fpage>496</fpage><lpage>512</lpage><pub-id pub-id-type="doi">10.1093/schbul/sbae011</pub-id><pub-id pub-id-type="pmid">38451304</pub-id><pub-id pub-id-type="pmcid">PMC11059785</pub-id></element-citation><mixed-citation id="mc-CR16" publication-type="journal">Wannan, C. M. J. et al. Accelerating Medicines Partnership&#174; Schizophrenia (AMP&#174; SCZ): Rationale and Study Design of the Largest Global Prospective Cohort Study of Clinical High Risk for Psychosis. <italic toggle="yes">Schizophr. Bull.</italic><bold>50</bold>, 496&#8211;512 (2024).<pub-id pub-id-type="pmid">38451304</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/schbul/sbae011</pub-id><pub-id pub-id-type="pmcid">PMC11059785</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR17"><label>17.</label><citation-alternatives><element-citation id="ec-CR17" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tognin</surname><given-names>S</given-names></name><etal/></person-group><article-title>PSYSCAN multi-centre study: baseline characteristics and clinical outcomes of the clinical high risk for psychosis sample</article-title><source>Schizophrenia Heidelb.</source><year>2025</year><volume>11</volume><fpage>66</fpage><pub-id pub-id-type="doi">10.1038/s41537-025-00598-x</pub-id><pub-id pub-id-type="pmid">40246889</pub-id><pub-id pub-id-type="pmcid">PMC12006469</pub-id></element-citation><mixed-citation id="mc-CR17" publication-type="journal">Tognin, S. et al. PSYSCAN multi-centre study: baseline characteristics and clinical outcomes of the clinical high risk for psychosis sample. <italic toggle="yes">Schizophrenia Heidelb.</italic><bold>11</bold>, 66 (2025).<pub-id pub-id-type="pmid">40246889</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41537-025-00598-x</pub-id><pub-id pub-id-type="pmcid">PMC12006469</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR18"><label>18.</label><citation-alternatives><element-citation id="ec-CR18" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Miettinen</surname><given-names>OS</given-names></name></person-group><article-title>Standardization of risk ratios</article-title><source>Am. J. Epidemiol.</source><year>1972</year><volume>96</volume><fpage>383</fpage><lpage>388</lpage><pub-id pub-id-type="doi">10.1093/oxfordjournals.aje.a121470</pub-id><pub-id pub-id-type="pmid">4643670</pub-id></element-citation><mixed-citation id="mc-CR18" publication-type="journal">Miettinen, O. S. Standardization of risk ratios. <italic toggle="yes">Am. J. Epidemiol.</italic><bold>96</bold>, 383&#8211;388 (1972).<pub-id pub-id-type="pmid">4643670</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/oxfordjournals.aje.a121470</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR19"><label>19.</label><citation-alternatives><element-citation id="ec-CR19" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Raballo</surname><given-names>A</given-names></name><etal/></person-group><article-title>Lack of transparency on baseline pharmacological treatments in Clinical High-Risk for psychosis (CHR-P) may degrade precision: A systematic review and meta-analysis</article-title><source>Eur. Neuropsychopharmacol.</source><year>2025</year><volume>93</volume><fpage>58</fpage><lpage>65</lpage><pub-id pub-id-type="doi">10.1016/j.euroneuro.2025.01.007</pub-id><pub-id pub-id-type="pmid">39986001</pub-id></element-citation><mixed-citation id="mc-CR19" publication-type="journal">Raballo, A. et al. Lack of transparency on baseline pharmacological treatments in Clinical High-Risk for psychosis (CHR-P) may degrade precision: A systematic review and meta-analysis. <italic toggle="yes">Eur. Neuropsychopharmacol.</italic><bold>93</bold>, 58&#8211;65 (2025).<pub-id pub-id-type="pmid">39986001</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.euroneuro.2025.01.007</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR20"><label>20.</label><citation-alternatives><element-citation id="ec-CR20" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Raballo</surname><given-names>A</given-names></name><name name-style="western"><surname>Poletti</surname><given-names>M</given-names></name><name name-style="western"><surname>Carpenter</surname><given-names>WT</given-names></name></person-group><article-title>Rethinking the Psychosis Threshold in Clinical High Risk</article-title><source>Schizophr. Bull.</source><year>2019</year><volume>45</volume><fpage>1</fpage><lpage>2</lpage><pub-id pub-id-type="doi">10.1093/schbul/sby149</pub-id><pub-id pub-id-type="pmid">30339224</pub-id><pub-id pub-id-type="pmcid">PMC6293213</pub-id></element-citation><mixed-citation id="mc-CR20" publication-type="journal">Raballo, A., Poletti, M. &amp; Carpenter, W. T. Rethinking the Psychosis Threshold in Clinical High Risk. <italic toggle="yes">Schizophr. Bull.</italic><bold>45</bold>, 1&#8211;2 (2019).<pub-id pub-id-type="pmid">30339224</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/schbul/sby149</pub-id><pub-id pub-id-type="pmcid">PMC6293213</pub-id></mixed-citation></citation-alternatives></ref></ref-list></back></article></pmc-articleset>